Nucleoside antiviral therapy for HBV-related hepatic carcinoma: Observation of post-operative prognosis

ObjectiveTo evaluate the nucleoside anologues antiviral therapy clinical outcome for HBV-related primary hepatic carcinoma patients after hepatectomy.

MethodsThe clinical data was collected on 100 cases of HBV-related carcinoma after hepatectomy that were selected from March 2010 to March 2014 in the hospital. Out of them, 50 cases were retrospectively analyzed as control group receiving hepatic transarterial chemoembolization (TACE) surgery and the other 50 cases as treatment group had TACE surgery followed by nucleoside analog treatment.

ResultsAfter two and three years of treatment, the HBV-DNA negativity was 100% and 0% in treatment and control group respectively (P < 0.05), Furthermore, recurrene rate were decreased in treatment group.The 2 and 3 years of survival rates were 50.0% and 46.0% in the treatment group and 30.0% and 24.0%. in the control group respectively(P < 0.05).

ConclusionThe nucleoside anti-viral treatment for HBV-related primary hepatic carcinoma patients after hepatectomy effectively inhibits the replication of HBV, uttermostly delays recurrence and improves the patient's survival rate.